open access

Vol 10, No 6 (2014)
Review paper
Published online: 2015-01-07
Get Citation

Novel treatment strategies in advanced melanoma: clinical data analysis with regards to registered indications in Poland

Jacek Mackiewicz, Marek Siemiątkowski, Cezary Ścibiorski, Krzysztof Krzemieniecki
Onkol. Prak. Klin 2014;10(6):336-343.

open access

Vol 10, No 6 (2014)
REVIEW ARTICLES
Published online: 2015-01-07

Abstract

An enormous progress can be observed over recent years in the treatment of advanced melanoma. First of all, there are great expectations regarding active immunotherapy, and ipilimumab, registered in Poland in 2011 allows long-term survival in some patients. Another therapeutic strategy involves specific molecularly targeted therapies, such as BRAF kinase inhibitors — vemurafenib and dabrafenib. These two classes of drugs are characterized by different kinetics of response (ipilimumab — late, but frequently long-lasting response, however apparent only in some patients; vemurafenib and dabrafenib — quick, but often only temporary response in most patients). BRAF inhibitors are particularly recommended for patients with rapid disease progression. Particular caution should be exercised when administering ipilimumab, due to its specific profile of side effects (e.g. immune-mediated reactions), which demands an early diagnostic and appropriate patient education, but most of all, the patients should be managed according to predetermined algorithms. A lot of ongoing trials using diverse immunotherapeutics and kinase inhibitors, in monotherapy or in combination therapy, create new possibilities for improvement of the therapeutic effects in patients with advanced melanoma.

Abstract

An enormous progress can be observed over recent years in the treatment of advanced melanoma. First of all, there are great expectations regarding active immunotherapy, and ipilimumab, registered in Poland in 2011 allows long-term survival in some patients. Another therapeutic strategy involves specific molecularly targeted therapies, such as BRAF kinase inhibitors — vemurafenib and dabrafenib. These two classes of drugs are characterized by different kinetics of response (ipilimumab — late, but frequently long-lasting response, however apparent only in some patients; vemurafenib and dabrafenib — quick, but often only temporary response in most patients). BRAF inhibitors are particularly recommended for patients with rapid disease progression. Particular caution should be exercised when administering ipilimumab, due to its specific profile of side effects (e.g. immune-mediated reactions), which demands an early diagnostic and appropriate patient education, but most of all, the patients should be managed according to predetermined algorithms. A lot of ongoing trials using diverse immunotherapeutics and kinase inhibitors, in monotherapy or in combination therapy, create new possibilities for improvement of the therapeutic effects in patients with advanced melanoma.

Get Citation

Keywords

melanoma, ipilimumab, vemurafenib, dabrafenib, trametinib, combination therapi

About this article
Title

Novel treatment strategies in advanced melanoma: clinical data analysis with regards to registered indications in Poland

Journal

Oncology in Clinical Practice

Issue

Vol 10, No 6 (2014)

Article type

Review paper

Pages

336-343

Published online

2015-01-07

Bibliographic record

Onkol. Prak. Klin 2014;10(6):336-343.

Keywords

melanoma
ipilimumab
vemurafenib
dabrafenib
trametinib
combination therapi

Authors

Jacek Mackiewicz
Marek Siemiątkowski
Cezary Ścibiorski
Krzysztof Krzemieniecki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl